What it sells
We make injections as easy as pushing a button!
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma partner business development / product teams licensing or co-developing an auto-injector presentation (inferred).
Trigger: what makes them buy now?
Needle anxiety delays initiation and hurts adherence; partners want device-driven brand differentiation and persistency. Claims 93% of patients and 88% of prescribers would switch in category research.
Workflow: what inputs become what output?
Patient twists off cap, presses OnePush to skin, hidden needle inserts, doses, auto-retracts and locks out; pharma partners co-develop injectable programs in the device via 505(b)(2) / 351(k) pathways.
Economics: what it saves and how it charges
Platform partnerships and own pipeline of improved injectable presentations; US-manufactured with automated lines in development. Product candidates are investigational; no pricing.
Distribution: how it reaches customers
Partnership/co-development with pharma companies via contact form.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.